{"id":"W3201548322","doi":"10.1093/noajnl/vdab112.036","title":"SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; University of Calgary; McGill University Health Centre","funders":"","keywords":"Temozolomide; Medicine; Sunitinib; Internal medicine; Oncology; Hazard ratio; Adjuvant; Phases of clinical research; Progression-free survival; Radiation therapy; Clinical trial; Chemotherapy; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002351938,0.0004537956,0.001182448,0.000186676,0.0002458837,0.0000243456,0.0001206377,0.0002330969,0.00004607795],"category_scores_gemma":[0.0005023243,0.0003470849,0.0001665794,0.0003461626,0.0002377247,0.0003043018,0.00005054878,0.0002130559,0.000001961987],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001261285,"about_ca_system_score_gemma":0.0003133822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001655574,"about_ca_topic_score_gemma":0.00008834229,"domain_scores_codex":[0.997087,0.0004249464,0.000792643,0.0008378362,0.0003617069,0.0004958866],"domain_scores_gemma":[0.9971214,0.001082503,0.0006386435,0.0004076388,0.0004464424,0.0003033567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1523714,0.03265763,0.0237295,0.0002182667,0.0009219427,0.0007732761,0.0009682265,0.00003743496,0.2647404,0.00004893818,0.00222679,0.5213062],"study_design_scores_gemma":[0.4564282,0.1343117,0.004547878,0.0001272006,0.0006826441,0.00007639117,0.0001904503,0.0002301538,0.3622213,0.00005181711,0.04069072,0.0004415559],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881901,0.005061068,0.00007476034,0.0009554274,0.0007482424,0.004391558,0.000469398,0.00007864145,0.00003078867],"genre_scores_gemma":[0.9942334,0.002070826,0.0009485669,0.0006521401,0.000172158,0.001067806,0.0007705623,0.00006743505,0.00001713152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5208646,"threshold_uncertainty_score":0.9998981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01452681636841457,"score_gpt":0.311337398229012,"score_spread":0.2968105818605974,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}